Akute Chorioretinopathia centralis serosa nach Immunisierung mit SARS-CoV-2-mRNA-Impfstoff?

• Literatur

• 1 Palacios AI, Rodríguez M, Martín MD. [Central serous chorioretinopathy of unusual etiology: A report of 2 cases]. Arch Soc Espanola Oftalmol 2014; 89: 275-278
• 2 Pereima RR, Bonatti R, Crotti F. et al. Ocular Adverse Events following Yellow Fever Vaccination: A Case Series. Ocul Immunol Inflamm 2021;
• 3 Foster BS, Agahigian DD. Central serous chorioretinopathy associated with anthrax vaccination. Retina 2004; 24: 624-625
• 4 Fowler N, Mendez Martinez NR, Pallares BV. et al. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine. Am J Ophthalmol Case Rep 2021; 23: 101136
• 5 Pauleikhoff L, Agostini H, Lange C. [Central serous chorioretinopathy]. Ophthalmologe 2021; 118: 967-980
• 6 Cheung CMG, Lee WK, Koizumi H. et al. Pachychoroid disease. Eye (Lond) 2019; 33: 14-33
• 7 Liu B, Deng T, Zhang J. Risk Factors for Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis. Retina 2016; 36: 9-19
• 8 Oken E, Kasper DL, Gleason RE. et al. Tetanus toxoid stimulation of the hypothalamic-pituitary-adrenal axis correlates inversely with the increase in tetanus toxoid antibody titers. J Clin Endocrinol Metab 1998; 83: 1691-1696
• 9 Fischer S, Gerriets T, Wessels C. et al. Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. Blood 2007; 110: 2457-2465
• 10 Kitzmann AS, Pulido JS, Diehl NN. et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008; 115: 169-173